LAG3 and neoplasm: In untreated metastatic or inoperable melanoma patients, combination treatment of Relatlimab (an anti-LAG-3 monoclonal antibody) with nivolumab demonstrates anti-tumor activity, significantly improving patients’ progression-free survival [376].